A Phase 1, Randomized, Three-Arm, Double-Blind, Single-Dose Study To Compare The Pharmacokinetics And Safety Of The Potential Biosimilar NeuLara With Ustekinumab In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- 05 Dec 2019 According to a NeuClone media release, dosing has been nearly completed in this trial.
- 17 Oct 2019 According to a NeuClone media release, dosing has been initiated in the trial.
- 17 Oct 2019 Status changed from planning to recruiting, according to a NeuClone media release.